AzTrials
AzTrials

Acute LeukemiaPhase 1NCT05320809

Study of 3D189 in Patients With Hematologic Malignancies

A Phase 1 study testing 3D189 in people with Acute Leukemia and Multiple Myeloma, run by 3D Medicines at 4 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
3D189
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
4 sitesChina
Study dates
1 Aug 2022to 4 Nov 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must be willing and able to understand and provide signed informed consent for the study.
  • Male or female patients ≥ 18 years of age on the day of signing informed consent.
  • Have a histologically or cytologically confirmed hematological malignancy and have achieved complete remission (CR) or partial remission (PR) after at least one line of standard therapy, and are not suitable for hematopoietic stem cell transplant (HSCT) for the following reasons: a) not eligible for HSCT due to intercurrent medical conditions; b) lack of an available HLA-matched donor for allogeneic HSCT; c) not able to accept HSCT for financial reasons; d) without a potential indication for HSCT (e.g. having a relatively favorable prognosis or low risk of relapse). However, patients who have previously received autologous HSCT but remain MRD+ or in remission after salvage therapy for post-transplant relapse are allowed to be recruited.
  • Including the following 4 types of hematological malignancies:
  • Acute Leukemia (AL): including acute myeloma leukemia (AML) and acute lymphoblastic leukemia (ALL), in morphological complete remission with complete or incomplete blood count recovery (CR or CRi), and having completed any planned post-remission therapy;
  • Myelodysplastic Syndrome (MDS): Revised International Prognostic Scoring System (IPSS-R) risk score > 3.5, having achieved CR or PR following prior therapy;
Show all 15Show fewer
  • Multiple Myeloma (MM): having achieved stringent complete response (sCR), CR or very good partial response (VGPR), or PR if deeper response cannot be obtained from adequate therapy.
  • Non-Hodgkin Lymphoma (NHL): preference for patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) who have achieved CR or PR following prior therapy.
  • Have a documented WT1 positive disease. This is defined as detectable presence of WT1 transcript via real-time quantitative polymerase chain reaction (RT-PCR) in patients'bone marrow or peripheral blood samples, or WT1 expression by immunohistochemistry (IHC) in archived (paraffin embedded, unstained slides) or freshly biopsied tumor tissues from bone marrow or lymph nodes or extranodal lesions ( for NHL patients).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0~1.
  • Estimated life expectancy ≥ 6 months.
  • The interval between the last antitumor therapy (including surgery, radiotherapy and systemic therapy) and the first study treatment must be at least 4 weeks or 10 half-lives of chemotherapy drugs (whichever is shorter), and the toxicity of the previous therapies have recovered to ≤ grade 1 [according to the Common Terminology Criteria for Adverse Events (CTCAE) 5.0], except for toxicity such as alopecia, which in the judgment of the investigator is not a safety risk.
  • Have adequate organ and bone marrow function, defined as follows:
  • 1) Blood count (participants must not have received transfusion of blood products within 7 days prior to this test): hemoglobin (Hb) ≥ 9.0 g/dL; neutrophil (NEUT) ≥ 1.0×109/L; platelet (PLT) ≥ 50×109/L; 2) Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ×ULN (upper limit of normal); but for subjects with liver metastasis, ALT or AST ≤ 5×ULN; total bilirubin (TBIL) ≤ 1.5 × ULN, or TBIL > 1.5 × ULN, but direct bilirubin (DBIL) ≤ 1.0 × ULN; 3) Renal function: serum creatinine ≤ 1.5 × ULN or endogenous creatinine clearance rate ≥ 50 ml/min (Cockcroft-Gault formula); 4) Coagulation: international normalized ratio (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN, unless subjects are receiving anticoagulant therapy as long as INR or APTT is within the therapeutic range of intended use of anticoagulants; 5) Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50% by echocardiography.
  • Subjects (including partners) must agree to use an adequate method of contraception, starting with the screening visit through 4 months after the last dose of study treatment.

Who cannot join

  • Previously treated with any therapy targeting WT1.
  • Have known hypersensitivity to peptide biologics, or to immune adjuvants Montanide and/or GM-CSF.
  • Subjects with acute promyelocytic leukemia (APL or M3).
  • Presence of central nervous system (CNS) invasion and/or carcinomatous meningitis; participants with previously cured brain or meningeal metastasis can be allowed.
  • Have undergone prior allogeneic HSCT, or plan to perform HSCT during the study period.
  • Received live vaccine within 4 weeks prior to the first dose of study treatment.
Show all 18Show fewer
  • Currently participate in or have participated in a study of an interventional agent or device within 4 weeks prior to the first dose of study treatment.
  • Have a known additional malignancies within the past 5 years, with the exception of cured skin basal cell carcinoma or cervical cancer in situ or other carcinoma in situ.
  • Have an active autoimmune disease or any disease that requires long-term use of systemic corticosteroids (at doses greater than 10 mg daily of prednisone equivalent) or any other form of immunosuppressive agents, hormone replacement therapy for adrenocortical insufficiency, hypopituitarism, hypothyroidism, or type I diabetes mellitus is not considered a form of systemic treatment and is allowed.
  • Have a diagnosis of primary immunodeficiency disease, or acquired immunodeficiency syndrome, or a positive test for human immunodeficiency virus (HIV).
  • Presence of active tuberculosis.
  • Have a history of a severe cardiovascular disease such as class III or IV heart failure [New York Heart Association (NYHA) criteria], myocardial infarction or stroke, unstable angina within 6 months prior to start of study treatment.
  • QTcF interval tested during the screening period ≥ 450 msec (for male subjects) or ≥ 470 msec (for female).
  • Have an acute severe infection requiring systemic therapy during the screening period.
  • Positive for HBsAg and HBV DNA ≥ 103 IU/ml; or positive for HCV antibodies and HCV RNA level is above the detection limit.
  • Are pregnant or breastfeeding, or have a positive serum pregnancy test during the screening period (for female subjects of childbearing potential).
  • Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Any condition, therapy or laboratory abnormality that, in the opinion of the investigator, might affect the participant's compliance, pose an unwarranted high risk to the participant, or interfere with the interpretation of the study results.

Trial locations and contacts

4 sites in 1 country.

China4 sites

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, 330006

  • Shengjing Hospital of China Medical

    Shengyang, Liaoning

  • Blood Disease Hospital , Chinese Academy of Medical Science

    Tianjing, Tianjing

Other trials in China

About this study

Official title: A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.

Read the detailed description

This is a phase 1, open-label, non-comparative, multicenter study of 3D189 (also known as galinpepimut-S), a multivalent peptide vaccine targeting Wilms Tumor-1 (WT1), for maintenance immunotherapy in patients with WT1-positive hematological malignancies, including patients with acute leukemia (AL) patients in complete remission (CR), or multiple myeloma (MM), non-Hodgkin lymphoma (NHL) or higher-risk myelodysplastic syndrome (MDS) patients who have received at least first-line standard therapy and recently achieved CR or partial remission (PR), if the latter is the best achievable response for the patient.

Being tested
3D189
Medical subject headings
Multiple Myeloma, Lymphoma, Non-Hodgkin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 3D189Biological

    3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.

    A maximum of 15 total injections of 3D189 will be administered as follows:

    1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.
    2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.
    3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52).
Study groups in NCT05320809
Study groupRoleWhat they receive
3D189ExperimentalNot described
Receives: Biological: 3D189

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number and frequency of TRAEs, including AE and SAEs (safety parameters)

    ncidence and severity of adverse events (AEs) and serious adverse events (SAEs) related to the study treatment (graded in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0)

    Measured: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 13 months

  2. Immune response rate of 3D189 vaccination among subjects

    The rate of positive results for any of the immune tests used to assess the WT1 -specific T-cell immune responses.

    Measured: From baseline (pre-treatment) to the end of study treatment,up to 12 months

Secondary outcomes (5)

  1. Overall survival (OS)

    From time of registration to the time of subject death.

    Measured: up to 24 months

  2. Relapse-free survival (RFS) or progression-free survival (PFS)

    From time of registration to the time of documented morphological leukemic relapse (for AL patients only) or disease progression (for MDS, MM and NHL patients) or subject death (for all patients)

    Measured: up to 12 months

  3. Overall response rate (ORR)

    Partial response (PR) or complete response (CR) in MDS, MM or NHL patients receiving 3D189 treatment, as evaluated by the investigators according to the corresponding response evaluation criteria and by comparison with baseline.

    Measured: up to 12 months

  4. Duration of Response (DoR)

    Time interval between the documentation of ORR (CR/PR) post study treatment and the documentation of progressive disease (PD) (for MDS, MM or NHL patients).

    Measured: up to 12 months

  5. Disease control rate (DCR)

    The percentage of patients who achieve CR or PR post study treatment or who remain stable for at least the first 12 weeks of study treatment (for MDS, MM or NHL patients).

    Measured: up to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Apr 2022
  2. Study start1 Aug 2022
  3. Primary completion4 Nov 2025
  4. Study completion4 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05320809
Sponsor's protocol ID
3D189-CN-001
Status last verified
Sep 2026
First submitted
19 Mar 2022
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing 3D189 in people with Acute Leukemia and Multiple Myeloma, run by 3D Medicines at 4 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number and frequency of TRAEs, including AE and SAEs (safety parameters) (time frame: From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 13 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05320809.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in